Step counter use in type 2 diabetes: a meta-analysis of randomized controlled trials

被引:73
|
作者
Qiu, Shanhu [1 ,2 ]
Cai, Xue [1 ]
Chen, Xiang [1 ]
Yang, Bingquan [1 ]
Sun, Zilin [1 ]
机构
[1] Southeast Univ, Sch Med, Inst Diabet, Zhongda Hosp,Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] Univ Ulm, Sect Sports Med & Rehabil, Dept Med 2, D-89075 Ulm, Germany
来源
BMC MEDICINE | 2014年 / 12卷
关键词
Step counter; Type; 2; diabetes; Physical activity; Glycemic control; Meta-analysis; Randomized controlled trial; PHYSICAL-ACTIVITY INTERVENTION; OLDER-ADULTS; CARDIORESPIRATORY FITNESS; SEDENTARY BEHAVIOR; TELEPHONE SUPPORT; HEALTH OUTCOMES; PEDOMETER; EXERCISE; PROGRAM; RISK;
D O I
10.1186/1741-7015-12-36
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: While step counter use has become popular among type 2 diabetes (T2D) patients, its effectiveness in increasing physical activity (PA) and improving glycemic control has been poorly defined. The aim of this meta-analysis of randomized controlled trials (RCTs) was to evaluate the association of step counter use with PA and glycemic control in T2D patients. Methods: Articles were identified by searches of PubMed, Web of Science and Cochrane Library from January 1994 to June 2013. RCTs in the English language were included, if they had assessed the effectiveness of step counters as motivating and monitoring tools in T2D patients, with reported changes in steps per day (steps/d) or glycosylated hemoglobin A1c (HbA1c), or both. Data were independently collected by 2 authors and overall estimates were made by a random-effects model. Results: Of the 551 articles retrieved, 11 RCTs were included. Step counter use significantly increased PA by 1,822 steps/d (7 studies, 861 participants; 95% confidence interval (Cl): 751 to 2,894 steps/d) in patients with T2D. Step counter use with a PA goal showed a bigger increase in PA (weighted mean difference (WMD) 3,200 steps/d, 95% Cl: 2,053 to 4,347 steps/d) than without (WMD 598 steps/d, 95% Cl: -65 to 1,260 steps/d). Further subgroup analysis suggested step counter use with a self-set PA goal (WMD 2,816 steps/d, 95% Cl: 1,288 to 4,344 steps/d) made no difference in increasing PA from a 10,000 steps/d goal (WMD 3,820 steps/d, 95% Cl: 2,702 to 4,938 steps/d). However, no significant HbA1c change was observed by step counter use (10 studies, 1,423 participants; WMD 0.02%, 95% Cl: -0.08% to 0.13%), either with (WMD 0.04%, 95% Cl: -0.21% to 0.30%) or without a PA goal (WMD 0.01%, 95% Cl: -0.10% to 0.13%). Conclusions: Step counter use is associated with a significant increase in PA in patients with T2D. However, evidence regarding its effect in improving glycemic control remains insufficient.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF DULAGLUTIDE IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Kanukula, R.
    Likhar, N.
    Mothe, R. K.
    Dang, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A198 - A199
  • [42] Effects of Exercise on Inflammatory Cytokines in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
    Chen, Xiaoke
    Sun, Xinzheng
    Wang, Chenghao
    He, Hui
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2020, 2020
  • [43] Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials
    Du, Qiang
    Wang, Yan-Jun
    Yang, Sheng
    Zhao, Yue-Yang
    Han, Ping
    [J]. ADVANCES IN THERAPY, 2014, 31 (11) : 1182 - 1195
  • [44] Effects of Probiotic Supplementation on Dyslipidemia in Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
    Wang, Chen
    Zhang, Chengcheng
    Li, Sijia
    Yu, Leilei
    Tian, Fengwei
    Zhao, Jianxin
    Zhang, Hao
    Chen, Wei
    Zhai, Qixiao
    [J]. FOODS, 2020, 9 (11)
  • [45] Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials
    Qian-Long Wu
    Ting Zheng
    Sheng-Zhen Li
    Jin-An Chen
    Zi-Chun Xie
    Jian-Mei Lai
    Ji-Yuan Zeng
    Jin-Ting Lin
    Jia-Shuan Huang
    Min-Hua Lin
    [J]. Diabetology & Metabolic Syndrome, 14
  • [46] Glycemic Control and Cardiovascular Events in Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
    Khraisat, Ahmad
    Bahekar, Amol
    Artin, Bassel
    Bhuriya, Rohit
    Al-Jaghbeer, Eshraq
    Singh, Sarabjeet
    Molnar, Janos
    Khosla, Sandeep
    Arora, Rohit
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A219 - A219
  • [47] Baduanjin Exercise for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Wen, Junmao
    Lin, Tong
    Cai, Yinhe
    Chen, Qianying
    Chen, Yuexuan
    Ren, Yueyi
    Weng, Senhui
    Wang, Boqing
    Ji, Shuliang
    Wu, Wei
    [J]. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2017, 2017
  • [48] Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials
    Zhang, Fudan
    Wang, Wenting
    Hou, Xu
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (03) : 478 - 488
  • [49] Efficacy of teplizumab for treatment of type 1 diabetes: A meta-analysis of randomized controlled trials
    Heidari, Ehsan
    Shafiee, Arman
    Noorian, Shahab
    Rafiei, Mohammad Ali
    Abbasi, Mohammad
    Amini, Mohammad Javad
    Safari, Omid
    Aghamahdi, Fatemeh
    Bakhtiyari, Mahmood
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2024, 40 (04)
  • [50] SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Shi, Nanjing
    Shi, Yetan
    Xu, Jingsi
    Si, Yuexiu
    Yang, Tong
    Zhang, Mengting
    Ng, Derry Minyao
    Li, Xiangyuan
    Xie, Fei
    [J]. FRONTIERS IN PUBLIC HEALTH, 2021, 9